CSF2 and neoplasm: By utilizing the patient’s tumor cells, this triple-function immunotherapy serves to expose the full repertoire of patient-specific tumor clonal neoantigens to the immune system, increase immune activity at the intradermal injection site in response to clonal neoantigen dendritic cell response with the aid of increased GM-CSF expression.